Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsFRA:59Z +0.62%82 Cyclically Adjusted PB Ratio is 1.07 as of Sep. 09, 2026, which is 1% below its 10-year median of 1.08. GuruFocus rates FRA:59Z with a GF Score™ of 82/100 and a GF Value™ of €15.10. The stock has 6 warning signs investors should review. Among 85 Medical Distribution companies, Medipal Holdings ranks worse than 50.59% on this metric.
The historical rank and industry rank for Medipal Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:59Z'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.77 Med: 1.08 Max: 1.62
Current: 1.08
During the past years, Medipal Holdings's highest Cyclically Adjusted PB Ratio was 1.62. The lowest was 0.77. And the median was 1.08.
FRA:59Z's Cyclically Adjusted PB Ratio is ranked worse than 50.59% of 85
companies
in the Medical Distribution industry
Industry Median: 1.08
vs FRA:59Z: 1.08
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Medipal Holdings's adjusted book value per share data for the three months ended in Mar. 2026 was €17.367. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €14.74 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Medipal Holdings (FRA:59Z) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Medipal Holdings Cyclically Adjusted PB Ratio Related Terms
Medipal Holdings Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medipal Holdings Cyclically Adjusted PB Ratio Chart
FRA:59Z vs MCK, COR, CAH: Cyclically Adjusted PB Ratio Comparison
For the Medical Distribution subindustry, Medipal Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings Cyclically Adjusted PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's Cyclically Adjusted PB Ratio falls into.
Medipal Holdings Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Medipal Holdings's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 1.07 mean?
Medipal Holdings (FRA:59Z) has a Cyclically Adjusted PB Ratio of 1.07 as of Sep. 09, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Medipal Holdings and its competitors. This is near median its historical median of 1.08. Over the past decade, Medipal Holdings' Cyclically Adjusted PB Ratio has ranged from 0.77 to 1.62. According to the industry distribution chart, Medipal Holdings ranks #43 out of 85 companies in the Medical Distribution industry, placing it in the top 50.6%.
Is Medipal Holdings' Cyclically Adjusted PB Ratio too high?
Medipal Holdings' current Cyclically Adjusted PB Ratio of 1.07 is near median its 10-year median of 1.08. Over the past 10 years, this metric has ranged from a low of 0.77 to a high of 1.62. The Medical Distribution industry median Cyclically Adjusted PB Ratio is 1.08. Medipal Holdings' value of 1.07 is 0.9% below this industry median. Based on the distribution chart, Medipal Holdings ranks #43 out of 85 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Medipal Holdings has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Cyclically Adjusted PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #43 out of 85 companies for Cyclically Adjusted PB Ratio. This places Medipal Holdings in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.08. Medipal Holdings' value of 1.07 is 0.9% below this benchmark. Historically, Medipal Holdings' own Cyclically Adjusted PB Ratio has ranged from 0.77 to 1.62 over the past decade. While the company's 10-year median is 1.08 vs. the industry median of 1.08, Medipal Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Distribution company?
The median Cyclically Adjusted PB Ratio among Medical Distribution companies is 1.08, based on 85 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current Cyclically Adjusted PB Ratio of 1.07 is 0.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Medipal Holdings and its competitors. For the Medical Distribution industry, the median Cyclically Adjusted PB Ratio is 1.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current Cyclically Adjusted PB Ratio is 1.07, which is near median its own 10-year median of 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Medipal Holdings (FRA:59Z) has a current Cyclically Adjusted PB Ratio of 1.07. The stock's GF Value™ is €15.10, compared to a current price of €15.70 — trading 4% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 1.07, which is near median its 10-year median of 1.08 and 0.9% below the Medical Distribution industry median of 1.08. Medipal Holdings' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Medipal Holdings (FRA:59Z), the current Cyclically Adjusted PB Ratio is 1.07 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (FRA:59Z) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of €15.70 is trading 4% above its estimated GF Value™ of €15.10.
Key valuation signals for FRA:59Z:
Cyclically Adjusted PB Ratio: 1.07 (near median its 10-year median of 1.08)
GF Value™: €15.10 vs. price of €15.70 (4% above fair value)
Industry Position: 0.9% below the Medical Distribution median (#43 of 85)
No single metric tells the full story. See the FRA:59Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
82GF Score
Get the complete analysis for FRA:59Z
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:59Z has been successfully added to your 
